10.23.15
Durham, N.C.-based Bioventus LLC has launched Supartz FX, which is a broadening of its current hyaluronic acid (HA) offering. Supartz FX has an expanded label allowing for repeat injection cycles to help knee osteoarthritis (OA) patients manage pain and remain active. More effective for pain and function than nonsteroidal anti-inflammatory drugs and corticosteroids, hyaluronic acids such as Supartz FX is a safe and effective treatment for knee OA.
Supartz FX helps restore the body’s natural HA production which may help preserve lubricity of bearing joint surfaces such as the knee and HA products, like Supartz FX, may also delay the need for total knee replacement.
“Supartz FX builds upon the success of Supartz and Artz to alleviate OA knee pain and since the introduction of SUPARTZ, more than 300 million injections of this HA have been prescribed globally,” said Tony Bihl, CEO, Bioventus. “The clinically proven expanded label allows Bioventus to continue to provide physicians and patients with an OA treatment that is safe for repeat courses of treatment.”
Supartz is currently only available in the United States.
Bioventus is an orthobiologics company
Supartz FX helps restore the body’s natural HA production which may help preserve lubricity of bearing joint surfaces such as the knee and HA products, like Supartz FX, may also delay the need for total knee replacement.
“Supartz FX builds upon the success of Supartz and Artz to alleviate OA knee pain and since the introduction of SUPARTZ, more than 300 million injections of this HA have been prescribed globally,” said Tony Bihl, CEO, Bioventus. “The clinically proven expanded label allows Bioventus to continue to provide physicians and patients with an OA treatment that is safe for repeat courses of treatment.”
Supartz is currently only available in the United States.
Bioventus is an orthobiologics company